/wp-content/uploads/logo.png00David Anderson/wp-content/uploads/logo.pngDavid Anderson2022-08-18 10:05:362022-09-06 10:37:20A phase 2 Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
/wp-content/uploads/logo.png00David Anderson/wp-content/uploads/logo.pngDavid Anderson2022-05-31 04:40:512022-05-31 08:06:34Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
/wp-content/uploads/logo.png00eallison/wp-content/uploads/logo.pngeallison2022-05-25 09:43:382022-05-25 09:58:16Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)
https://endeavorbiomedicines.com/wp-content/uploads/scrip-logo-1.svg52169Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-19 15:50:002022-01-19 15:50:00Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
https://endeavorbiomedicines.com/wp-content/uploads/Stat_News_logo-gray.svg100100Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-21 17:34:072022-01-21 17:47:16Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease
https://endeavorbiomedicines.com/wp-content/uploads/linkedin-gray.svg100100Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-31 18:09:392022-02-01 18:52:55My newest puzzle, Endeavor BioMedicines, and the chance to reverse a devastating pulmonary disease
/wp-content/uploads/logo.png00David Anderson/wp-content/uploads/logo.pngDavid Anderson2022-02-07 05:05:122022-02-10 08:50:07Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
